Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Imfinzi becomes first NHS drug for aggressive lung cancer

Summary by Pharmaphorum
AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer

2 Articles

PharmaphorumPharmaphorum
Center

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer

Read Full Article
pharmatimes.compharmatimes.com

Imfinzi approved for NHS use in limited-stage small cell lung cancer

Durvalumab becomes first immunotherapy recommended for LS-SCLC patients in England and Wales

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news in on Tuesday, September 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

NHS icon

NHS

United Kingdom icon

United Kingdom

News
For You
SearchBlindspotLocal